| Literature DB >> 20618958 |
Chiara Porro1, Silvia Lepore, Teresa Trotta, Stefano Castellani, Luigi Ratclif, Anna Battaglino, Sante Di Gioia, Maria C Martínez, Massimo Conese, Angela B Maffione.
Abstract
BACKGROUND: Microparticles (MPs) are membrane vesicles released during cell activation and apoptosis. MPs have different biological effects depending on the cell from they originate. Cystic fibrosis (CF) lung disease is characterized by massive neutrophil granulocyte influx in the airways, their activation and eventually apoptosis. We investigated on the presence and phenotype of MPs in the sputum, a rich non-invasive source of inflammation biomarkers, of acute and stable CF adult patients.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20618958 PMCID: PMC2910006 DOI: 10.1186/1465-9921-11-94
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Baseline characteristics of patients.
| 11 | 10 | 7 | ||
| Age (years) | 23.4 ± 4.3 | 24.5 ± 3.7 | 22.7 ± 3.5 | |
| Sex ratio (male:female) | 7:4 | 2:8 | 3:4 | |
| F508del homozygous | 5 | 2 | / | |
| F508del heterozygous | 4 | 7 | / | |
| Other mutations | 1 | 1 | / | |
| FEV1 (%) | 57.8 ± 7.0 | 49.6 ± 6.4 | 0.53 | 75.2 ± 8.4 |
| ΔFEV1 | 9.08 ± 2.5 | 0.07 ± 0.04 | 0.001 | / |
| CRP (mg/dl) | 0.53 ± 0.16 | 8.36 ± 2.87 | 0.01 | / |
| Clinical score | 7.3 ± 0.37 | 2.45 ± 0.31 | 0.001 | / |
| Source of infection: | ||||
| 11 | 6 | 3 | ||
| 3 | 3 | 0 | ||
| 0 | 2 | 0 | ||
| 0 | 1 | 0 | ||
FEV1, forced expiratory volume in 1 second as % predicted. In 1 stable CF patient analysis of CFTR mutations is missing. Statistically significant differences between stable and acute CF patients are shown.
Figure 1Identification of MPs by flow cytometry. Representative dot plots and histograms of MPs from sputum from CF patients and P. aeruginosa and S. aureus. MPs (A), P. aeruginosa PAO1 (B), S. aureus (C) and calibrator beads (10-μm; Beckman Coulter) are represented on a forward-scatter/side-scatter dot-plot histogram. MPs, defined as events with size of 0.1 to 1 μm in diameter, are gated in (a) window when compared with calibrator beads (CAL), gated in (b). Histograms showing the CD66b-FITC labelling of MPs from CF sputum (D), and the lack of staining obtained with control IgM, with P. aeruginosa PAO1 (E) or S. aureus (F).
Figure 2Transmission electron microscopy of MPs from the sputum of a CF patient. Multiple spherical particles, ranging from 100 to 500 nm, are visualized.
Figure 3Quantification of MPs in CF and PCD sputum. Total MPs present in sputum of CF and PCD patients. CF patients (n = 21) show a significant higher number of MPs respect to PCD patients (n = 7). *p = 0.00297.
Figure 4Phenotype of MPs present in sputa of acute and stable CF and PCD patients. In acute and stable CF patients, the number of MPs staining positive for FITC-conjugated antibodies directed against CD11a are significantly higher than in PCD patients (A). Stable CF vs. PCD: *p = 0.0464. Acute CF vs. PCD: *p = 0.0431. MPs positive to CD66b, both in acute and in stable phase of CF, are significantly elevated in respect to PCD (B). Stable CF vs. PCD: *p = 0.0373. Acute CF vs. PCD: **p = 0.0046. Positivity of MPs to CD11b is not significantly different in the three groups of patients (C).